Wnt5A Enhances Resistance of Melanoma Cells to Targeted BRAF Inhibitors
收藏官方服务：
资源简介：
Wnt5A Enhances Resistance of Melanoma Cells to Targeted BRAF Inhibitors
应用场景：
创建时间：
2014-03-06
相关数据集
Development of molecular intervention strategies for B-cell lymphoma
There are many genetic mutations involved in B-cell lymphomagenesis. These mutations contribute to the prognosis of B-cell lymphomas and can be used for and targeted for intervention. This review prov
DataCite Commons2021-03-30 更新90
The evolution of MET and NRAS gene amplification as sequential acquired resistance mechanisms in a patient with EGFR mutation positive non-small cell lung cancer
EGFR mutant non-small cell lung cancer patients disease demonstrates remarkable responses to EGFR targeted therapy, but inevitably they succumb to acquired resistance, which can be complex and difficu
NIAID Data Ecosystem70
Proteomics identifies markers of MAPKi resistance offering new therapeutic strategies in melanoma- Cytoplasmic (cyt), nuclear (ne) and secreted (sn) proteins of MAPKi sensitive melanoma cells
MAPK inhibitors (MAPKi) show outstanding clinical response rates in melanoma patients harbouring BRAF mutations, but resistance is common. High-throughput, subcellular proteome analyses at two differe
NIAID Data Ecosystem60
Targeting a newly-identified RNA polymerase II-associated PHF5A-PHF14-KMT2A transcriptional subcomplex with a KMT2A-WDR5 inhibitor impairs the self-renewal, pluripotency and in vivo tumorigenicity of pancreatic cancer stem cells
Pancreatic cancer remains one of the most aggressive and lethal cancers in humans. It is undeniably known for its notorious resistance to conventional chemotherapeutics which are often associated with
NIAID Data Ecosystem70
Gene expression profiling of oncogenic NRAS driven mouse melanomas that have developed resistance to NRAS withdrawal. Mus musculus
Targeted therapies have the potential to revolutionize cancer care by providing personalized treatment strategies that are less toxic and more effective but it is clear that for most solid tumors supp
NIAID Data Ecosystem70
